journal article·2018-11-05Open access

The role of MPL and imiquimod adjuvants in enhancement of immune response and protection in BALB/c mice immunized with solubleLeishmaniaantigen (SLA) encapsulated in nanoliposome

Tara Emami, Seyed Mahdi Rezayat, Ali Khamesipour, Rasool Madani, Gholamreza Habibi, Mansure Hojatizade, Mahmoud Reza Jaafari

Abstract

Adjuvants play an essential role in the induction of immunity against leishmaniasis. In this study, monophosphoryl lipid A (MPL) and imiquimod (IMQ) were used as TLR ligands adjuvants to enhance immunogenicity and rate of protection against leishmaniasis. Nanoliposomes containing soluble Leishmania antigens (SLA) and adjuvants were consisted of DSPC, DSPG and Chol prepared by using lipid film method followed by bath sonication. The size of nanoliposomes was around 95 nm and their zeta potential was negative. BALB/c mice were immunized by liposomal formulations of lip/SLA, lip/MPL/SLA, lip/IMQ/SLA, lip/MPL/IMQ/SLA, lip/SLA + lip/IMQ, lip/SLA + lip/MPL, lip/SLA + lip/MPL/IMQ and five controls of SLA, lip/MPL, lip/IMQ, lip/MPL/IMQ and buffer by subcutaneously (SC) injections, three times in 2 weeks intervals. The synergic effect of two adjuvants when they are used in one formulation showed significantly (p < .001) smaller footpad swelling and the lowest parasite burden in lymph node and foot after the challenge. IgG2a in these groups showed the higher titre compared to control groups, which is compatible with the high IFN-γ production and lowest IL-4. Taken together the results indicated that co-delivery of MPL and IMQ adjuvants and antigen in nanoliposome carrier could be an appropriate delivery system to induce cellular immunity pathway against leishmaniasis.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Research on Leishmaniasis Studies · Toxin Mechanisms and Immunotoxins · Toxoplasma gondii Research Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran;

Department of Proteomics and Biochemistry, Razi Vaccine and Serum Research Institute, Agricultural Research Education and Extension Organization(AREEO), Karaj, Iran;

Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran;

Department of Parasite Vaccine Research and Production, Razi Vaccine and Serum Research Institute, Agricultural Research Education and Extension Organization(AREEO), Karaj, Iran;

Department of Basic Medical Sciences, Neyshabur University of Medical Sciences, Neyshabur, Iran;

Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran;

Department of Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Funding

Tehran University of Medical Sciences · School of Advanced Technologies in Medicine · Razi Vaccine and Serum Research Institute

References (57)

Show source-provided references
1. 10.1371/journal.pone.003567110.1371/journal.pone.0035671 ↗
2. 10.1517/14712598.2014.94541510.1517/14712598.2014.945415 ↗
3. 10.1016/j.vaccine.2009.05.08410.1016/j.vaccine.2009.05.084 ↗
4. 10.1073/pnas.89.20.994410.1073/pnas.89.20.9944 ↗
5. 10.1111/j.1365-3024.2009.01116.x10.1111/j.1365-3024.2009.01116.x ↗
6. 10.1016/j.vaccine.2005.02.01510.1016/j.vaccine.2005.02.015 ↗
7. Nadim A · Bull Soc Pathol Exot Filiales · 1983 · 76 · 377
8. Sjölander A · J Immunol · 1998 · 160 · 394910.4049/jimmunol.160.8.3949 ↗
9. 10.1002/jlb.50.1.9310.1002/jlb.50.1.93 ↗
10. 10.1016/S0952-7915(06)80032-410.1016/S0952-7915(06)80032-4 ↗
11. 10.1007/s12026-008-8016-210.1007/s12026-008-8016-2 ↗
12. 10.1186/s13071-016-1777-x10.1186/s13071-016-1777-x ↗
13. 10.1016/j.exppara.2014.08.01610.1016/j.exppara.2014.08.016 ↗
14. 10.1007/s00436-011-2806-510.1007/s00436-011-2806-5 ↗
15. 10.1016/j.vaccine.2012.03.04010.1016/j.vaccine.2012.03.040 ↗
16. 10.1016/j.actatropica.2013.07.02110.1016/j.actatropica.2013.07.021 ↗
17. 10.1084/jem.2002014710.1084/jem.20020147 ↗
18. Mohan T · Indian J Med Res · 2013 · 138 · 779
19. 10.1177/205101361454144010.1177/2051013614541440 ↗
20. 10.1016/j.exppara.2008.12.01510.1016/j.exppara.2008.12.015 ↗
21. 10.1016/j.colsurfb.2009.06.02510.1016/j.colsurfb.2009.06.025 ↗
22. 10.1016/j.exppara.2012.09.00110.1016/j.exppara.2012.09.001 ↗
23. 10.1080/21691401.2017.129064710.1080/21691401.2017.1290647 ↗
24. 10.3109/21691401.2014.95363310.3109/21691401.2014.953633 ↗
25. 10.1007/s10450-016-9767-z10.1007/s10450-016-9767-z ↗
26. 10.1038/nature0973710.1038/nature09737 ↗
27. 10.1128/IAI.01527-0710.1128/IAI.01527-07 ↗
28. Cluff CW. Monophosphoryl lipid a (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Berlin, Germany: Springer; 2009. p. 111–123.10.1007/978-1-4419-1603-7_10 ↗
29. 10.1371/journal.pntd.000309110.1371/journal.pntd.0003091 ↗
30. 10.1177/205101361774157810.1177/2051013617741578 ↗
31. 10.1084/jem.2005172010.1084/jem.20051720 ↗
32. 10.1016/j.clindermatol.2003.08.01210.1016/j.clindermatol.2003.08.012 ↗
33. Scott P · J Immunol · 1987 · 139 · 22110.4049/jimmunol.139.1.221 ↗
34. 10.1016/0003-2697(84)90782-610.1016/0003-2697(84)90782-6 ↗
35. 10.1016/j.ab.2010.11.01510.1016/j.ab.2010.11.015 ↗
36. 10.1016/j.vaccine.2006.04.06210.1016/j.vaccine.2006.04.062 ↗
37. 10.1111/j.1365-3024.1985.tb00098.x10.1111/j.1365-3024.1985.tb00098.x ↗
38. 10.1016/j.vaccine.2012.11.08010.1016/j.vaccine.2012.11.080 ↗
39. 10.1038/sj.icb710001110.1038/sj.icb7100011 ↗
40. 10.1016/j.vaccine.2007.05.04210.1016/j.vaccine.2007.05.042 ↗
41. 10.1021/mp200249410.1021/mp2002494 ↗
42. 10.1586/14760584.2.2.23910.1586/14760584.2.2.239 ↗
43. 10.1007/s10227-004-0803-310.1007/s10227-004-0803-3 ↗
44. 10.2165/00128071-200405060-0001010.2165/00128071-200405060-00010 ↗
45. 10.1016/j.jim.2007.11.01210.1016/j.jim.2007.11.012 ↗
46. 10.1016/j.ajps.2014.09.00410.1016/j.ajps.2014.09.004 ↗
47. 10.1016/j.exppara.2006.07.00210.1016/j.exppara.2006.07.002 ↗
48. 10.1155/2016/548208710.1155/2016/5482087 ↗
49. 10.3390/pharmaceutics402027610.3390/pharmaceutics4020276 ↗
50. 10.3389/fcimb.2013.0001310.3389/fcimb.2013.00013 ↗
51. 10.1016/j.jconrel.2012.10.02010.1016/j.jconrel.2012.10.020 ↗
52. 10.1016/j.molimm.2017.09.01010.1016/j.molimm.2017.09.010 ↗
53. 10.1016/j.jmii.2014.01.00610.1016/j.jmii.2014.01.006 ↗
54. 10.1371/journal.pntd.000142910.1371/journal.pntd.0001429 ↗
55. 10.1016/S1674-8301(10)60004-810.1016/S1674-8301(10)60004-8 ↗
56. 10.1038/nbt1184-97910.1038/nbt1184-979 ↗
57. 10.1016/j.ijpharm.2011.01.04410.1016/j.ijpharm.2011.01.044 ↗